RPL4

Across TCGA pan-cancer cohorts, RPL4 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPL4 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL4 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

LUAD, COAD, and LSCC are the cancer types where RPL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.449	0.893	.023	8	view →
COAD	DFS	Median	II,III,IV	1.000	0.896	.049	6	view →
LSCC	DFS	Quartile	III,IV	0.549	1.000	.034	4	view →
UCEC	DFS	Median	II,III,IV	0.883	0.543	.037	4	view →
PDAC	DFS	Tertile	IV	0.199	0.726	.024	3	view →
CCRCC	OS	Tertile	III,IV	0.547	0.818	.026	2	view →
GBM	OS	Median	All	0.546	0.246	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPL4–LUAD (OS)

Open the LUAD breakdown →